Publications by authors named "F Cacace"

The objective of this study is to demonstrate the potential of a multicompartmental mathematical model to simulate the activity of the gastrointestinal system after the intake of drugs, with a limited number of parameters. The gastrointestinal system is divided into five compartments, modeled as both continuous systems with discrete events (stomach and duodenum) and systems with delay (jejunum, ileum, and colon). The dissolution of the drug tablet occurs in the stomach and is described through the Noyes-Whitney equation, with pH dependence expressed through the Henderson-Hasselbach relationship.

View Article and Find Full Text PDF

Objective: Fractures of the proximal humerus (PHF) are commonly treated conservatively. Evidence suggests that a period of immobilization of one week or less may lead to some advantages compared to a traditional 3-4 weeks of immobilization. The purpose of this systematic review was to assess the clinical and radiological results in the case of early rehabilitation vs.

View Article and Find Full Text PDF

Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse.

View Article and Find Full Text PDF
Article Synopsis
  • A phase 3 clinical trial evaluated the effectiveness and safety of adding eltrombopag to standard immunosuppressive therapy (horse ATG plus cyclosporine) in treating patients with severe aplastic anemia.
  • Results showed a higher complete response rate at 3 months (22% with eltrombopag vs. 10% without) and improved overall response rates at 6 months (68% vs. 41%).
  • The addition of eltrombopag enhanced the treatment's efficacy without increasing severe side effects, suggesting it could be a beneficial option for newly diagnosed patients.
View Article and Find Full Text PDF
Article Synopsis
  • * The introduction of targeted therapies, such as multiple generations of BCR-ABL1 inhibitors (like imatinib and ponatinib) and BTK inhibitors (like ibrutinib), has revolutionized treatment for CML and CLL, significantly improving patient outcomes and potentially allowing some patients to discontinue therapy.
  • * While PI3K inhibitors are effective in CLL, they are used less frequently due to side effects
View Article and Find Full Text PDF